Phase II Study of Pembrolizumab in the Immunoreactive Ovarian Cancer Subtype

Project: Research project

Project Details

Description

Phase II Study of Pembrolizumab in the Immunoreactive Ovarian Cancer Subtype
StatusActive
Effective start/end date3/6/193/30/26

Funding

  • UNIVERSITY OF CALIFORNIA, LOS ANGEL
  • MERCK

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.